Data from the OrigAMI-4 trial support the accelerated approval of amivantamab and hyaluronidase-lpuj for this HNSCC population.
|Articles|July 1, 1998
Oncology NEWS International
- Oncology NEWS International Vol 7 No 7
- Volume 7
- Issue 7
New Director of AIDS Research
BETHESDA, Md--NIH director Harold Varmus, MD, has named Neal Nathanson, MD, to serve as the new director of NIH’s Office of AIDS Research (OAR). Dr. Nathanson, a leader in viral pathogenesis, comes to the NIH from the University of Pennsylvania Medical Center, where he was Vice Dean for Research and Research Training. He is an active member of the NIH AIDS Vaccine Research Committee, chaired by Dr. David Baltimore.
Advertisement
BETHESDA, Md--NIH director Harold Varmus, MD, has named Neal Nathanson, MD, to serve as the new director of NIHs Office of AIDS Research (OAR). Dr. Nathanson, a leader in viral pathogenesis, comes to the NIH from the University of Pennsylvania Medical Center, where he was Vice Dean for Research and Research Training. He is an active member of the NIH AIDS Vaccine Research Committee, chaired by Dr. David Baltimore.
Articles in this issue
over 28 years ago
Calling the National Cancer Instituteover 28 years ago
Six Cycles of AT Found Safe in Advanced Breast Cancerover 28 years ago
New Drug Promising in Advanced Pancreatic Cancerover 28 years ago
Herceptin/Chemo Effective in Metastatic Breast Cancerover 28 years ago
Virtual Reality Exhibit Simulates Cancer Fatigueover 28 years ago
Exhibit Explores Healing Power of Creating Artworkover 28 years ago
Update on Trials of Thrombopoietin for Platelet Recoveryover 28 years ago
Amifostine Reduces Xerostomia After RT for Head and Neck Cancerover 28 years ago
National Survey Documents Gap in Quality of HIV/AIDS CareAdvertisement
Related to this article
Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.
Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.
Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.
The FDA assigned an April 9, 2027, target action date to resubmitted applications for rivoceranib plus camrelizumab in unresectable or metastatic hepatocellular carcinoma.
Adam C. Olson, MD, MSc-GH, discussed letting patients choose between modalities with comparably strong evidence, and the data that shaped his approach.
Data from the phase 3 MANGROVE study support the application for zanubrutinib/rituximab in this mantle cell lymphoma population.
Sunnie Kim, MD, discussed perioperative durvalumab plus FLOT, ctDNA-guided de-escalation, irAE monitoring, and biomarkers in gastroesophageal cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
Setting Up an HDR Brachytherapy Program Amid a National Decline
3
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
4
16-Fraction PMRT With IMN Irradiation Noninferior in High-Risk Breast Cancer
5